Annals of Surgical Oncology

, Volume 15, Issue 5, pp 1322–1329 | Cite as

Outcomes of Locoregional Recurrence after Surgical Chest Wall Resection and Reconstruction for Breast Cancer

  • Alfredo A. Santillan
  • John V. Kiluk
  • John M. Cox
  • Tammi L. Meade
  • Nathon Allred
  • Daniel Ramos
  • Jeff King
  • Charles E. CoxEmail author
Breast Oncology



Locoregional chest wall recurrences involving ribs and/or sternum after primary surgical treatment predict a poor outcome in patients with breast cancer. The precise natural history and surgical outcome of these chest wall recurrences are not fully understood. The objective of this study is to clarify the clinicopathological features of chest wall recurrence of breast cancer and evaluate prognostic factors predicting survival after chest wall resection and reconstruction (CWRR).


A total of 28 patients who underwent CWRR at the H. Lee Moffitt Cancer Center between December 1999 and September 2007 were retrospectively analyzed. Overall survival was calculated by the Kaplan–Meier method and the significance of prognostic variables was evaluated by log-rank and Cox regression analyses.


The postoperative morbidity and mortality was 21% and 0%, respectively. Overall 5-year survival for the entire cohort was 18%. Disease-free interval <24 months (P = 0.03) and triple-negative phenotype (P = 0.002) were the only independent predictors of survival. Overall 1-, 2-, and 5-year survival rates for the triple-negative phenotype were 38%, 23%, and 0%, respectively. In contrast, overall 1-, 2-, and 5-year survival rates for the non-triple-negative phenotype were 100%, 70%, and 39%, respectively.


Radical chest wall resection can be done without mortality and acceptable morbidity to accomplish long-term palliation. The strongest predictor of overall survival was the triple-negative phenotype. Because the triple-negative phenotype is not amenable to any form of therapy, palliative resection may be warranted. Development of appropriate targeted therapies to this population of patients is critical.


Breast carcinoma Chest wall resection Chest wall recurrence Estrogen receptor Progesterone receptor HER2/neu 


  1. 1.
    Andry G, Suciu S, Vico P, et al. Locoregional recurrences after 649 modified radical mastectomies: incidence and significance. Eur J Surg Oncol 1989; 15:476–85PubMedGoogle Scholar
  2. 2.
    Arragiada R, Le MG, Rochard F, et al. Conservative treatment versus mastectomy in early breast cancer: patterns of failure with 15 years of follow-up data. Institut Gustave-Roussy Breast Cancer Group. J Clin Oncol 1996; 14:1558–64Google Scholar
  3. 3.
    Schmoor C, Sauerbrei W, Bastert G, et al. Role of isolated locoregional recurrence of breast cancer: results of four prospective studies. J Clin Oncol 2000; 18:1696–708PubMedGoogle Scholar
  4. 4.
    Clemons M, Danson S, Hamilton T, et al. Locoregionally recurrent breast cancer: incidence, risk factors and survival. Cancer Treat Rev 2001; 27:67–82PubMedCrossRefGoogle Scholar
  5. 5.
    Taghian A, Jeong JH, Mamounas E, et al. Patterns of locoregional failure in patients with operable breast cancer treated by mastectomy and adjuvant chemotherapy with or without tamoxifen and without radiotherapy: results from five National Surgical Adjuvant Breast and Bowel Project randomized clinical trials. J Clin Oncol 2004; 22:4247–54PubMedCrossRefGoogle Scholar
  6. 6.
    Faneyte IF, Rutgers EJ, Zoetmulder FA. Chest wall resection in the treatment of locally recurrent breast carcinoma: indications and outcome for 44 patients. Cancer 1997; 80:886–91PubMedCrossRefGoogle Scholar
  7. 7.
    Pameijer CR, Smith D, McCahill LE, et al. Full-thickness chest wall resection for recurrent breast carcinoma: an institutional review and meta-analysis. Am Surg 2005; 71:711–15PubMedGoogle Scholar
  8. 8.
    Early Breast Cancer Trialists’ Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomized trials. Lancet 2005; 365:1687–717CrossRefGoogle Scholar
  9. 9.
    Bedwinek J. Natural history and management of isolated local-regional recurrence following mastectomy. Semin Radiat Oncol 1994; 4:260–9PubMedCrossRefGoogle Scholar
  10. 10.
    Aberizk WJ, Silver B, Henderson IC, et al. The use of radiotherapy for treatment of isolated locoregional recurrence of breast carcinoma after mastectomy. Cancer 1986; 58:1214–18PubMedCrossRefGoogle Scholar
  11. 11.
    Snyder AF, Farrow GM, Masson JK, et al. Chest-wall resection for locally recurrent breast cancer. Arch Surg 1968; 97:246–53PubMedGoogle Scholar
  12. 12.
    Shah JP, Urban JA. Full thickness chest wall resection for recurrent breast carcinoma involving the bony chest wall. Cancer 1975; 35:567–73PubMedCrossRefGoogle Scholar
  13. 13.
    Miyauchi K, Koyama H, Noguchi S, et al. Surgical treatment for chest wall recurrence of breast cancer. Eur J Cancer 1992; 28A:1059–62PubMedCrossRefGoogle Scholar
  14. 14.
    Toi M, Tanaka S, Bando M, et al. Outcome of surgical resection of chest wall recurrence in breast cancer patients. J Surg Oncol 1997; 64:23–6PubMedCrossRefGoogle Scholar
  15. 15.
    Downey RJ, Rusch V, Hsu FI, et al. Chest wall resection for locally recurrent breast cancer: is it worthwhile? J Thorac Cardiovasc Surg 2000; 119:420–8PubMedCrossRefGoogle Scholar
  16. 16.
    Chagpar A, Meric-Bernstam F, Hunt KK, et al. Chest wall recurrence after mastectomy does not always portend a dismal outcome. Ann Surg Oncol 2003; 10:628–34PubMedCrossRefGoogle Scholar
  17. 17.
    Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumors. Nature 2000; 406:747–52PubMedCrossRefGoogle Scholar
  18. 18.
    Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001; 98:10869–74PubMedCrossRefGoogle Scholar
  19. 19.
    Fisher B, Anderson S, Fisher ER, et al. Significance of ipsilateral breast tumor recurrence after lumpectomy. Lancet 1991; 338:327–31PubMedCrossRefGoogle Scholar
  20. 20.
    Fisher B, Anderson S, Bryant J, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 2002; 347:1233–41PubMedCrossRefGoogle Scholar
  21. 21.
    Schuck A, Konemann S, Matthees B, et al. Radiotherapy in the treatment of locoregional relapses of breast cancer. Br J Radiol 2002; 75:663–9PubMedGoogle Scholar
  22. 22.
    Waeber M, Castiglione-Gertsch M, Dietrich D, et al. Adjuvant therapy after excision and radiation of isolated postmastectomy locoregional breast recurrence: definitive results of phase III randomization trial (SAKK 23/82) comparing tamoxifen with observation. Ann Oncol 2003; 14:1215–21PubMedCrossRefGoogle Scholar
  23. 23.
    Livasy CA, Karaca G, Nanda R, et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol 2006: 19:264–71PubMedCrossRefGoogle Scholar
  24. 24.
    Foulkes WE, Stefansson IM, Chappuis PO, et al. Germiline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst 2003; 95:1482–5PubMedGoogle Scholar
  25. 25.
    Bauer KR, Brown M, Cress RD, et al. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype. Cancer 2007; 109:1721–8PubMedCrossRefGoogle Scholar
  26. 26.
    Peduzzi P, Concato J, Feinstein AR, Holford TR. Importance of events per independent variable in proportional hazards regression analysis. II. Accuracy and precision of regression estimates. J Clin Epidemiol 1995; 48:1503–10PubMedCrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2008

Authors and Affiliations

  • Alfredo A. Santillan
    • 1
  • John V. Kiluk
    • 1
  • John M. Cox
    • 1
  • Tammi L. Meade
    • 1
  • Nathon Allred
    • 1
  • Daniel Ramos
    • 1
  • Jeff King
    • 1
  • Charles E. Cox
    • 1
    Email author
  1. 1.Departments of Surgery at the Comprehensive Breast Cancer ProgramH. Lee Moffitt Cancer Center and Research Institute, University of South FloridaTampaUSA

Personalised recommendations